December 29, 2011 — A budesonide/formoterol pressurized metered dose inhaler (pMDI) reduced chronic obstructive pulmonary disease (COPD) exacerbations more effectively than a formoterol dry powder ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

February 28, 2007 (San Diego) — Combined therapy with the inhaled corticosteroid budesonide and the long-acting beta-agonist formoterol ( Symbicort) produces bronchodilation as rapidly as does ...

Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

asthma, lungs The combination therapy significantly reduced the risk of severe exacerbations and improved lung function. Topline results were announced from two phase 3 studies evaluating a fixed-dose ...

In a recent study published in the Annals of Internal Medicine, researchers performed a randomized, placebo-controlled trial (RCT) among adults with confirmed severe acute respiratory syndrome ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...

Asthma-inhaler-resize_G_514410525 The SYGMA trials assessed the use of an as-needed combined corticosteroid/beta-agonist inhaler in patients with mild asthma. Level 2 ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...

"The global budesonide inhaler market is set for robust growth as increasing respiratory disorders and the expansion of generic alternatives drive demand for affordable, effective inhalation therapies ...